1. FEJEZET | HIVATKOZÁSOK

  1. WHO Hereditary Diseases Programme. Report of a Joint WHO/ WFH Meeting on the Possibilities for the Prevention and Control of Haemophilia, Geneva, 26-28 March 1990. Geneva, Switzerland: World Health Organization; 1990. https://apps.who.int/iris/ handle/10665/60986. Hozzáférés: 2020. január 14.
  2. WHO Human Genetics Programme. Delivery of Treatment for Haemophilia: Report of a Joint WHO/WFH/ISTH Meeting, London, United Kingdom, 11-13 February 2002. London, UK: World Health Organization; 2002. https://apps.who.int/iris/handle/10665/67792. Hozzáférés: 2020. január 14.
  3. World Health Organization. The World Health Report 2003: Shaping the Future. Geneva, Switzerland: World Health Organization; 2003. https://www.who.int/whr/2003/en/whr03_en.pdf?ua=1. Hozzáférés: 2020. január 14.
  4. Global Conference on Primary Health Care. Global Conference on Primary Health Care: Declaration of Astana. Geneva, Switzerland: World Health Organization; 2018. https://www.who.int/docs/default-source/primary-health/declaration/gcphc-declaration.pdf. Hozzáférés: 2020. január 14.
  5. WHO Regional Office for Europe, Health Services Delivery Programme. Integrated Care Models: An Overview (Working Document). Geneva, Switzerland: World Health Organization; 2016. https://web-prod.who.int/primary-health/conference-phc/declaration. Hozzáférés: 2020. január 14.
  6. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia. 2008;14(2):361-374.
  7. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism. Haemophilia. 2000;6(3):131-134.
  8. Dunkley S, Lam JCM, John MJ, et al. Principles of haemophilia care: the Asia-Pacific perspective. Haemophilia. 2018;24(3):366-375.
  9. Council of Europe, Committee of Ministers. Resolution CM/ Res(2017)43 on Principles Concerning Haemophilia Therapies (Replacing Resolution CM/Res(2015)3). Council of Europe, Committee of Ministers: Strasbourg, France; 2017. https://www. edqm.eu/sites/default/ files/resolution_cm_res_2017_43_on_princ iples_concerning_haemophilia_therapies.pdf. Hozzáférés: November 14, 2019.
  10. Evatt B. Guide to Developing a National Patient Registry. Montreal, Canada: World Federation of Hemophilia; 2005. https://www1. wfh. org/publications/files/pdf-1288.pdf. Hozzáférés: November 14, 2019.
  11. Keipert C, Hesse J, Haschberger B, et al. The growing number of hemophilia registries: quantity vs. quality. Clin Pharmacol Ther. 2015;97(5):492-501.
  12. Coffin D, Herr C, O’Hara J, et al. World bleeding disorders registry: the pilot study. Haemophilia. 2018;24(3):e113-e116.
  13. World Federation of Hemophilia. World Bleeding Disorders Registry. Montreal, QC: World Federation of Hemophilia website; 2019. https://www.wfh.org/en/our-work-research-data/world-bleeding-disorders-registry. Hozzáférés: 2019. október 22.
  14. Stoffman J, Andersson NG, Branchford B, et al. Common themes and challenges in hemophilia care: a multinational perspective. Hematology. 2019;24(1):39-48.
  15. European Medicines Agency, Pharmacovigilance and Epidemiology and Regulatory and Science Management Departments. Report on Haemophilia Registries-Workshop 8 June 2018. London, UK: European Medicines Agency; 2018. https://www.ema.europa.eu/en/ documents/report/report-haemophilia-registries-workshop_ en.pdf. Hozzáférés: 2020. április 18.
  16. Farrugia A. Guide for the Assessment of Clotting Factor Concentrates. Montreal, Canada: World Federation of Hemophilia; 2017. https:// www1.wfh.org/publication/files/pdf-1271.pdf. Hozzáférés: November 14, 2019.
  17. O’Mahony B. Guide to National Tenders for the Purchase of Clotting Factor Concentrates. Montreal, Canada: World Federation of Hemophilia; 2015. https://www1.wfh.org/publication/files/pdf- 1294.pdf. Hozzáférés: 2019. október 24.
  18. Poonnoose P, Carneiro JDA, Cruickshank AL, et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage—the MUSFIH study. Haemophilia. 2017;23(4):538-546.
  19. van den Berg HM. From treatment to prevention of bleeds: what more evidence do we need? Haemophilia. 2017;23(4):494-496.
  20. World Federation of Hemophilia. WFH Online Registry of Clotting Factor Concentrates. Montreal: World Federation of Hemophilia; 2019. https://elearning.wfh.org/resource/online-cfc-registry/. Hozzáférés: 2019. szept. 25.
  21. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382(1):29-40.
  22. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215-2227.
  23. Giangrande PLF, Hermans C, O’Mahony B, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2018;13(1):66.
  24. Van den Bossche D, Peerlinck K, Jacquemin M. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement. Int J Lab Hematol. 2018;40(Suppl 1):21-29.
  25. Al-Allaf FA, Abduljaleel Z, Bogari NM, et al. Identification of six novel factor VIII gene variants using next generation sequencing and molecular dynamics simulation. A cta Biochim Pol. 2019;66(1):23-31.
  26. Al-Allaf FA, Taher MM, Abduljaleel Z, et al. Molecular analysis of factor VIII and factor IX genes in hemophilia patients: identification of novel mutations and molecular dynamics studies. J Clin Med Res. 2017;9(4):317-331.
  27. Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC. Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol. 2014;89(4):375-379.
  28. Lyu C, Xue F, Liu X, et al. Identification of mutations in the F8 and F9 gene in families with haemophilia using targeted high-throughput sequencing. Haemophilia. 2016;22(5):e427-e434.
  29. Manderstedt E, Nilsson R, Lind-Hallden C, Ljung R, Astermark J, Hallden C. Targeted re-sequencing of F8, F9 and VWF: characterization of Ion Torrent data and clinical implications for mutation screening. PLoS ONE. 2019;14(4):e0216179.
  30. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta- analytic approach using national registries. A nn Intern Med. 2019;171(8):540-546.
  31. Pierce GF, Haffar A, Ampartzidis G, et al. First-year results of an expanded humanitarian aid programme for haemophilia in resource- constrained countries. Haemophilia. 2018;24(2):229-235.
  32. Giangrande PL, Black C. World Federation of Haemophilia programs in developing countries. Semin Thromb Hemost. 2005;31(5):555-560.
  33. Fischer K, Poonnoose P, Dunn AL, et al. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia. 2017;23(1):11-24.
  34. Fowler H, Lacey R, Keaney J, Kay-Jones C, Martlew V, Thachil J. Emergency and out of hours care of patients with inherited bleeding disorders. Haemophilia. 2012;18(3):e126-e131.
  35. Khair K, Meerabeau L, Gibson F. Self-management and skills acquisition in boys with haemophilia. Health Expect. 2015;18(5):1105-1113.
  36. Breakey VR, Ignas DM, Warias AV, White M, Blanchette VS, Stinson JN. A pilot randomized control trial to evaluate the feasibility of an Internet-based self-management and transitional care program for youth with haemophilia. Haemophilia. 2014;20(6):784-793.
  37. Lee Mortensen G, Strand AM, Almen L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review. Haemophilia. 2018;24(6):862-872.
  38. Breakey VR, Blanchette VS, Bolton-Maggs PH. Towards comprehensive care in transition for young people with haemophilia. Haemophilia. 2010;16(6):848-857.
  39. Croteau SE, Padula M, Quint K, D’Angelo L, Neufeld EJ. Center-based quality initiative targets youth preparedness for medical independence: HEMO-Milestones tool in a comprehensive hemophilia clinic setting. Pediatr Blood Cancer. 2016;63(3):499-503.
  40. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389-398.
  41. Schrijvers LH, Schuurmans MJ, Fi scher K. Promoting selfmanagement and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia. 2016;22(4):499-506.
  42. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939.
  43. van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134(3):317-320.
  44. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
  45. Blamey G, Forsyth A, Zourikian N, et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia—a global perspective. Haemophilia. 2010;16(Suppl 5):136-145.
  46. Paroskie A, Gailani D, DeBaun MR, Sidonio RF Jr. A cross-sectional study of bleeding phenotype in haemophilia A carriers. Br J Haematol. 2015;170(2):223-228.
  47. Hermans C, Kulkarni R. Women with bleeding disorders. Haemophilia. 2018;24(Suppl 6):29-36.
  48. Osooli M, Donfield SM, Carlsson KS, et al. Joint comorbidities among Swedish carriers of haemophilia: a register-based cohort study over 22 years. Haemophilia. 2019;25(5):845-850.
  49. Radic CP, Rossetti LC, Abelleyro MM, et al. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation. J Thromb Haemost. 2015;13(4):530-539.
  50. Zimmermann R, Staritz P, Huth-Kuhne A. Challenges in treating elderly patients with haemophilia: a focus on cardiology. Thromb Res. 2014;134(Suppl 1):S48-S52.
  51. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood. 2009;114(26):5256-5263.
  52. Angelini D, Konkle BA, Sood SL. Aging among persons with hemophilia: contemporary concerns. Semin Hematol. 2016;53(1):35-39.
  53. Angelini D, Sood SL. Managing older patients with hemophilia. Hematology Am Soc Hematol Educ Program. 2015;2015:41-47.
  54. Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis. 2011;22(5):402-406.
  55. Sood SL, Cheng D, Ragni M, et al. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018;2(11):1325-1333.
  56. Alperstein W, Corrales-Medina FF, Tamariz L, Palacio AM, Davis JA. Prevalence of hypertension (HTN) and cardiovascular risk factors in a hospitalized pediatric hemophilia population. J Pediatr Hematol Oncol. 2018;40(3):196-199.
  57. Makris M, Konkle BA. Hepatitis C in haemophilia: time for treatment for all. Haemophilia. 2017;23(2):180-181.
  58. World Health Organization. International Classification of Functioning, Disability and Health (ICF). World Health Organization; 2001. https://www.who.int/classifications/icf/en/. Hozzáférés: 2019. november 5.
  59. Poonnoose PM, Srivastava A. Outcome assessment in hemophilia. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. 3rd ed. New York, United States: Blackwell Publishing Ltd; 2019:253-261.
  60. Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: defining patient important outcomes. Res Pract Thromb Haemost. 2019;3(2):184-192.
  61. Porter I, Goncalves-Bradley D, Ricci-Cabello I, et al. Framework and guidance for implementing patient-reported outcomes in clinical practice: evidence, challenges and opportunities. J Comp Eff Res. 2016;5(5):507-519.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.